OPKO HEALTH INC (OPK) Stock Price, Forecast & Analysis
USA - NASDAQ:OPK - US68375N1037 - Common Stock
OPK Key Statistics, Chart & Performance
The current stock price of OPK is 1.32 USD. In the past month the price decreased by -13.51%. In the past year, price decreased by -18.99%.
OPK Latest News, Press Relases and Analysis
OPK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.21 | 97.37B | ||
| CI | THE CIGNA GROUP | 9.6 | 72.84B | ||
| LH | LABCORP HOLDINGS INC | 16.49 | 21.68B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.16 | 20.92B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 106.61 | 19.26B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.58B | ||
| DVA | DAVITA INC | 12.54 | 8.28B | ||
| HIMS | HIMS & HERS HEALTH INC | 65.17 | 7.95B | ||
| CHE | CHEMED CORP | 19.68 | 6.31B | ||
| RDNT | RADNET INC | 213.12 | 6.23B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 31.88 | 5.76B | ||
| OPCH | OPTION CARE HEALTH INC | 18.87 | 4.56B |
Related stock screener links
About OPK
Company Profile
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,997 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Company Info
OPKO HEALTH INC
4400 Biscayne Blvd.
Miami FLORIDA 33137 US
CEO: Phillip Frost
Employees: 2997
Phone: 13055754181
OPKO HEALTH INC / OPK FAQ
Can you describe the business of OPKO HEALTH INC?
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,997 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Can you provide the latest stock price for OPKO HEALTH INC?
The current stock price of OPK is 1.32 USD. The price increased by 3.13% in the last trading session.
Does OPK stock pay dividends?
OPK does not pay a dividend.
What is the ChartMill technical and fundamental rating of OPK stock?
OPK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of OPKO HEALTH INC (OPK) based on its PE ratio?
OPKO HEALTH INC (OPK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
Can you provide the growth outlook for OPKO HEALTH INC?
The Revenue of OPKO HEALTH INC (OPK) is expected to decline by -12.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for OPKO HEALTH INC?
OPKO HEALTH INC (OPK) has a market capitalization of 1.05B USD. This makes OPK a Small Cap stock.
OPK Technical Analysis
OPK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPK. The financial health of OPK is average, but there are quite some concerns on its profitability.
OPK Financial Highlights
Over the last trailing twelve months OPK reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 19.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.04% | ||
| ROE | -13.82% | ||
| Debt/Equity | 0.26 |
OPK Forecast & Estimates
10 analysts have analysed OPK and the average price target is 3.98 USD. This implies a price increase of 201.36% is expected in the next year compared to the current price of 1.32.
For the next year, analysts expect an EPS growth of -64.33% and a revenue growth -12.6% for OPK